Archives

Should everybody be taking Ozempic? | Front Burner

We examine the rise and risks of blockbuster drugs like Ozempic, after the WHO conditionally recommended GLP-1 medications for the long-term treatment of obesity. »»» Subscribe to CBC News to watch more videos: http://bit.ly/1RreYWS For breaking news, video, audio and in-depth coverage: https://www.cbc.ca/news Follow CBC News on TikTok: https://www.tiktok.com/@cbcnews Subscribe to CBC News on Snapchat: […]

Eli Lilly drug candidate trial sees major weight loss, knee pain relief

In a phase 3 trial, Eli Lilly’s experimental drug retatrutide delivered an average 28.7% weight loss and reduced pain among adults with obesity or overweight and knee osteoarthritis.  The trial recruited 445 participants and divided them equally to receive retatrutide 9 milligrams, retatrutide 12 milligrams or a placebo for 68 weeks, according to a Dec. […]

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

Eli Lilly and Company LLY is one of the two companies that dominate the booming cardiometabolic space, driven by its successful GLP-1 therapies — Mounjaro for diabetes and Zepbound for weight loss, both comprising the same ingredient, tirzepatide, a dual GIP/GLP-1 RA. Despite facing strong competition from Novo Nordisk’s NVO semaglutide medicines, Ozempic for diabetes and Wegovy […]

Can Intuitive Surgical Weather GLP-1 Drag on Bariatric Surgery?

Intuitive Surgical ISRG faces a persistent headwind in one of its historically important U.S. procedure categories, namely bariatric surgery. For six consecutive quarters, domestic bariatric volumes have declined in the high single digits, a trend the company directly links to the rapid adoption of GLP-1 weight-loss drugs. Management confirmed that bariatric now represents less than […]

Lilly’s Next-Gen Obesity Shot Shows Best-In-Class Weight Loss In Study

Lilly’s Next-Gen Obesity Shot Shows Best-In-Class Weight Loss In Study Shares of Eli Lilly are higher in premarket trading after the company unveiled blowout topline results for its next-generation obesity drug retatrutide, which delivered more than 23% weight loss over 68 weeks – the strongest performance yet for a late-stage obesity trial. Adult patients in […]

The 11 Biggest GLP-1 Myths, Busted by Expert Dietitians

If you’ve spent any time on social media lately, you might have seen conflicting claims about GLP-1 weight loss medications. One post says they’ll completely kill your appetite. Another warns about scary side effects. Someone else declares losing weight this way is “cheating.” With all the noise out there, it’s tough to know what’s actually […]

Here’s How GLP-1 Affected MGP Ingredients (MGPI) in Q3

Mairs & Power, an investment advisor, released the third-quarter 2025 investor letter for the “Mairs & Power Small Cap Fund.” A copy of the letter can be downloaded here. The market’s concentration persists in 2025, with a few dominant mega-cap stocks tied to artificial intelligence (AI) driving most of the favorable outcomes. The fund returned […]